Stocks
Rapport Therapeutics, Inc.RAPP
NASDAQHealthcareBiotechnology$29.82
Price as of · delayed, not real-time
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neurological disorders, targeting receptor-associated proteins to modulate synaptic function. Its lead program, RAP-219, is in Phase 2 for temporal lobe epilepsy, with additional preclinical assets for neuropathic pain and other CNS conditions. Investors track the stock for its differentiated approach to CNS drug development and early-stage clinical catalysts.
52W Range: $23.75-$52.93
Congressional Interest in Rapport Therapeutics, Inc. (RAPP)
No congressional trades have been disclosed for Rapport Therapeutics, Inc. (RAPP) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading RAPP?
No congressional trades found for this stock.